Haloperidol Dosing for Sedation in Adults
For acute sedation of agitated adults, start with haloperidol 0.5-1 mg IV/IM, with repeat doses of 0.5-1 mg every 1-2 hours as needed, up to a maximum of 10 mg daily (5 mg daily in elderly patients). 1
Clinical Context and Dosing Algorithm
The recommended approach depends on the clinical scenario:
For Delirium with Agitation
- Initial dose: 0.5-1 mg orally or subcutaneously at night and every 2 hours when required 1
- Titration: Increase in 0.5-1 mg increments as needed
- Maximum: 10 mg daily (5 mg daily in elderly patients)
- Severe distress or immediate danger: Consider higher starting dose of 1.5-3 mg 1
- If agitation persists: Add a benzodiazepine (lorazepam 0.5-1 mg or midazolam 2.5-5 mg) 1
For Acute Undifferentiated Agitation (Emergency Setting)
- Standard dose: 5 mg IM has been the most studied dose in emergency settings 2
- Alternative: 0.5-1 mg for elderly or frail patients 3
- Repeat dosing: Can be given every 20-30 minutes to 2 hours as needed 4
For Pediatric/Adolescent Patients (12-16 years)
- Adolescent dose: 0.5-1 mg initially, may repeat every 20-30 minutes 4
- Child dose: 0.25-0.5 mg 4
- Maximum: 30-40 mg daily depending on age 4
Evidence Quality and Nuances
The evidence base for haloperidol in acute agitation is substantial but reveals important considerations:
Dose-response relationship: Multiple studies comparing 5 mg haloperidol to benzodiazepines show equivalent efficacy 2, but recent evidence suggests lower doses (≤0.5 mg) may be equally effective with better safety profiles in elderly patients 5. A 2023 study found no patients receiving ≤0.5 mg required repeat doses within 4 hours, compared to patients receiving higher doses, with additional benefits in length of stay and restraint use 5.
Combination therapy: The combination of haloperidol with lorazepam shows superior efficacy to haloperidol alone in palliative care settings, with a 2017 RCT demonstrating significantly greater reduction in agitation scores (mean difference -1.9 points on RASS) 6. However, a 2022 study found that adding diphenhydramine to haloperidol-lorazepam combinations (the "B52" cocktail) increased adverse events including hypotension and oxygen desaturation without improving efficacy 7.
Critical Safety Considerations
QTc prolongation: All antipsychotics prolong QTc interval at maximum recommended doses, though none exceeded 500 ms in systematic reviews 2. The FDA label warns about cardiac dysrhythmias 8.
Extrapyramidal symptoms (EPS): Risk increases with higher doses and in younger male patients 4. The 2013 retrospective study found significantly greater sedation risk with doses >1 mg in 24 hours 9.
Contraindications:
- Parkinson's disease or Dementia with Lewy Bodies (absolute contraindication due to severe EPS risk) 8
- Hypersensitivity reactions including anaphylaxis 8
Special populations:
- Elderly: Use 0.25-0.5 mg starting doses; maximum 5 mg daily 1
- Renal impairment: Reduce subcutaneous infusion doses 1
- Pregnancy: Use only if benefit clearly outweighs risk; neonates at risk for withdrawal symptoms 8
Common Pitfalls to Avoid
Overdosing elderly patients: The 2013 study found 37.5% of hospitalized elderly patients received >1 mg initial doses despite guidelines recommending 0.5 mg, resulting in higher sedation rates without improved efficacy 9
Ignoring reversible causes: Always address hypoxia, urinary retention, constipation, and medication effects before escalating doses 1
Combining with lithium: Risk of irreversible encephalopathic syndrome; monitor closely for neurological toxicity 8
Using in anticholinergic toxicity: Haloperidol's anticholinergic effects can worsen agitation from anticholinergic or sympathomimetic poisoning 2
Route-Specific Considerations
Subcutaneous administration: Same doses as oral/IM can be given subcutaneously, or as continuous infusion of 2.5-10 mg over 24 hours 1
Onset times:
The most recent high-quality evidence supports starting with lower doses (0.5-1 mg) in most patients, particularly the elderly, with careful titration based on response rather than reflexive use of higher doses that increase adverse events without improving efficacy.